The evidence-based science of brain photobiomodulation (PBM) is well-documented in over 20+ years of academic research and 600+ peer-reviewed papers. We partner with top research institutions to develop 1st-in-class wearable digital therapeutics.
Brain Pacer Efficacy Study (Healthy Subjects)
City University of New York (CUNY)
Phase 2 Study
Harvard University/Massachusetts General Hospital (MGH), China Medical University (CMU/Taiwan)
Depression (MDD) in Child and Adolescent
Phase 2 Study
Attention-Deficit/Hyperactivity Disorder (ADHD)
Phase 1 Study
Stanford University, Hospital de Clinicas de Porto Alegre (Brazil), Institute of Neuroscience (INS, Italy)
ADHD with Autistic Traits in Child and Adolescent
ASD (Autism) in Adult/Child and Adolescent
In the News:
“At Mass. General, Paolo Cassano… is working on one of several pilot studies nationwide of transcranial infrared light therapy [which is] believed to decrease inflammation and oxidative stress in the brain as well as increase the formation of neurons.”
“Cassano thinks light therapy could provide a groundbreaking new tool for depression treatment — one that is affordable, without side effects and more immediate than medication.”
“New research at Massachusetts General Hospital is showing that it may be able to treat severe depression with the use of specialized light and without medication.”
“Exposure to a light that isn’t visible to the naked eye may be the next breakthrough treatment for depression. Massachusetts General Hospital psychiatrist Paolo Cassano, MD, PhD, and other researchers at MGH and elsewhere, are seeing encouraging results in studies of near-infrared light—the light closest on the spectrum to visible light.”
Our Scientific Advisory Board (SAB) provides strategic guidance and direction for our research and scientific programs. The SAB is comprised of leaders in brain health and psychological treatment research, clinical practice, and advocacy, who are integral to furthering Niraxx’ mission. Learn more.
Alvaro Pascual-Leone, MD, PHD
Dr. Pascual-Leone is a Professor of Neurology at Harvard Medical School and Director of the Berenson-Allen Center at Beth Israel Deaconess Medical Center. His research aims at understanding the mechanisms that control brain plasticity across the life to prevent age-related cognitive decline, reduce the risk for dementia, and minimize the impact of neurodevelopmental disorders.
Maurizio Fava, MD
Dr. Fava founded and was Director of Massachusetts General Hospital’s (MGH) Depression Clinical and Research Program (DCRP), one of the most highly regarded depression programs in the U.S. He is a world leader in the field of depression and has authored and co-authored more than 800 original articles published in medical journals with international circulation.
Michael Hamblin, Phd
Dr. Hamblin is a Principal Investigator at MGH’s Wellman Center for Photomedicine, the world’s largest academic research facility dedicated to investigating the effects of light on human biology and to the development of photothearpy for multiple diseases. He is a world leader in the field of photomedicine.
Maria A. Franceschini, PHD
Dr. Franceschini is an Associate Professor in Radiology at Harvard Medical School. She is a pioneer in the field of near-infrared spectroscopy (NIRS), or the use of near-infrared light to quantify changes in hemoglobin concentration. Her research focuses on developing NIRS for brain health.
Jacek Dmochowski, PhD
Jacek is an Assistant Professor in the Department of Biomedical Engineering at the City College of New York. His research is focused on developing novel non-invasive techniques for sensing and modulating brain activity with the overall goal of improving brain function in health and disease. He leverages his expertise in machine learning to optimize interventions and decode the brain.
Andre, R. Brunoni, Md, Phd
Dr. Brunoni is Director of two clinical and research centers at the University of Sao Paulo. His research focuses on the use of non-invasive brain stimulation techniques to treat multiple brain diseases.